| Literature DB >> 32529072 |
Hua Yang1, Paul J Carney1, Jessie C Chang1, James Stevens1.
Abstract
Of the eighteen hemagglutinin (HA) subtypes (H1-H18) that have been identified in bats and aquatic birds, many HA subtypes have been structurally characterized. However, several subtypes (H8, H11 and H12) still require characterization. To better understand all of these HA subtypes at the molecular level, HA structures from an A(H4N6) (A/swine/Missouri/A01727926/2015), an A(H8N4) (A/turkey/Ontario/6118/1968), an A(H11N9) (A/duck/Memphis/546/1974), an A(H14N5) A/mallard/Gurjev/263/1982, and an A(H15N9) (A/wedge-tailed shearwater/Western Australia/2576/1979 were determined by X-ray crystallography at 2.2Å, 2.3Å, 2.8Å, 3.0Å and 2.5Å resolution, respectively. The interactions between these viruses and host receptors were studied utilizing glycan-binding analyses with their recombinant HA. The data show that all avian HAs retain their strict binding preference to avian receptors, whereas swine H4 has a weak human receptor binding. The molecular characterization and structural analyses of the HA from these zoonotic influenza viruses not only provide a deeper appreciation and understanding of the structure of all HA subtypes, but also re-iterate why continuous global surveillance is needed.Entities:
Keywords: A(H11N9); A(H14N5); A(H15N9); A(H4N6); A(H8N4); Avian; Biomolecules; Glycobiology; Hemagglutinin; Influenza virus; Microbiology; Proteins; Receptor binding; Swine; Viral protein; Virology
Year: 2020 PMID: 32529072 PMCID: PMC7281811 DOI: 10.1016/j.heliyon.2020.e04068
Source DB: PubMed Journal: Heliyon ISSN: 2405-8440
Figure 1Influenza A virus HA phylogenetic tree. The HAs can be divided into group-1 and group-2, which can both be subdivided into subgroups. The discussed structures of H8 and H11 in group 1 are highlighted in blue, while H4, H14 and H15 in group 2, are highlighted in green. H12 HA, which is colored in red, is the only HA not in the Protein Data Bank (PDB).
Recombinant HA proteins used in this study.
| Strain (Subtype) | Accession Number | Abbreviation | |
|---|---|---|---|
| GISAID | NCBI | ||
| A/swine/Missouri/A01727926/2015 (H4N6) | EPI_ISL_213836 | swH4 | |
| A/turkey/Ontario/6118/1968 (H8N4) | EPI_ISL_70124 | avH8 | |
| A/duck/Memphis/546/1974 (H11N9) | EPI_ISL_69885 | avH11 | |
| A/mallard/Gurjev/263/1982 (H14N5) | EPI_ISL_14744 | avH14 | |
| A/wedge-tailed shearwater/Western Australia/2576/1979 (H15N9) | EPI_ISL_8917 | avH15 | |
| A/Switzerland/9715293/2013 | – | HuH3 | |
| A/Vietnam/1203/2004 | AvH5 | ||
Crystallization, data collection and refinement statistics for the HA crystal structures.
| swH4 | avH8 | avH11 | avH14 | avH15 | |
|---|---|---|---|---|---|
| Protein Conc. (mg/ml) | 14 | 13 | 15 | 17 | 14 |
| Crystallization conditions | 0.1M Tris-HCl, pH8.5, 30% (w/v) PEG 1000 | 0.05M Magnesium Chloride, 0.1M HEPES:NaOH pH7.5, 30% (v/v) PEG 550 MME | 0.1M MOPS, pH7.0, 18% (w/v) PEG 4000 | 0.2M Sodium cacodylate trihydrate pH5.5, 20% (w/v) PEG4000 | 0.1M Sodium acetate trihydrate, pH5.0, 20% (v/v) PEG 4000 |
| Cryoprotectant | None | None | 20% glycerol | 20% glycerol | None |
| Beamline collected | APS, 22-ID | APS, 22-ID | APS, 22-ID | APS, 22-BM | APS, 22-ID |
| Space group | P21 | C2 | P212121 | C2 | C2 |
| Cell dimensions (Å) | 68.97, 240.01, 68.95 | 170.05, 98.09, 132.74 | 80.12, 121.15, 217.73 | 174.67,100.97, 236.08 | 108.67, 101.38, 163.27 |
| Cell angle (º) | 90, 119.86, 90 | 90.00, 115.20, 90.00 | 90, 90, 90 | 90.00, 103.93, 90.00 | 90, 90.74, 90 |
| Resolution (Å) | 50–2.20 (2.26–2.20) | 50–2.25 (2.33–2.25) | 50–2.8 (2.90–2.80) | 50–3.0 (3.11–3.0) | 50–2.5 (2.59–2.5) |
| Total reflections | 96492 (8968) | 94690 (8943) | 52133 (4302) | 82593 (7598) | 63339 (5739) |
| Unique reflections | 95270 (8892) | 91870 (8031) | 47619 (4051) | 79186 (7388) | 61139 (5600) |
| Rsym | 0.087(0.47) | 0.085 (0.77) | 0.12 (0.55) | 0.116 (0.56) | 0.069 (0.61) |
| Rpim | 0.059 (0.31) | 0.069 (0.37) | 0.044 (0.26) | 0.104 (0.47) | 0.036 (0.44) |
| I/sigma | 29.5 (3.6) | 15.2 (1.8) | 25.8/5.6 | 7.7 (1.7) | 21.8 (1.8) |
| Completeness (%) | 98.0 (99.7) | 98.2 (96.8) | 93.1 (100) | 99.9 (100) | 99.9 (99.8) |
| Redundancy | 3.3 (3.4) | 3.8 (3.3) | 8.1 (5.8) | 3.8 (3.7) | 3.8 (3.5) |
| CC1/2 | 0.99 (0.74) | 1 (1) | 1 (0.99) | 1 (1) | 1 (1) |
| Resolution (Å) | 50–2.20 (2.26–2.20) | 50–2.25 (2.33–2.25) | 50–2.8 (2.9–2.8) | 50–3.0 (3.11–3.0) | 50–2.5 (2.59–2.50) |
| No. reflections | 95259 (8889) | 91046 (8030) | 47362 (4050) | 79094 (7388) | 61079 (5592) |
| No. reflections (test) | 4767 (446) | 4563 (383) | 2370 (207) | 3949 (355) | 3098 (296) |
| Rwork/Rfree | 20.3/24.4 | 18.7/22.5 | 23.4/27.8 | 22.4/26.0 | 23.0/26.5 |
| No. of atoms | 11706 | 11928 | 11712 | 23322 | 11781 |
| B Values (Å2) | 49.30 | 47.70 | 58.31 | 60.30 | 65.84 |
| Wilson B value (Å2) | 50.68 | 35.31 | 55.12 | 44.24 | 55.10 |
| r.m.s.d.- bond length (Å) | 0.010 | 0.012 | 0.011 | 0.009 | 0.011 |
| r.m.s.d.- bond angle (º) | 1.228 | 1.275 | 1.811 | 1.795 | 1.488 |
| Favored (%) | 94.3 | 96.1 | 94.7 | 92.6 | 93.1 |
| Outliers (%) | 0.6 | 0.3 | 0.3 | 0.6 | 1.0 |
| 6V44 | 6V46 | 6V47 | 6V48 | 6V49 | |
Numbers in parentheses refer to the highest resolution shell.
CC1/2 Pearson correlation coefficient between two random half data sets.
Reference (Davis et al., 2007).
Figure 2The overall structure of HA monomer. A. The overall structure of group-1 avH8 monomer, with occupied glycosylation sites shown as sticks. B. The overall structure of group-1 avH11 monomer with occupied glycosylation sites shown as sticks. C. The overall structure of avH14 monomer with occupied glycosylation sites shown as sticks. D. The overall structure of avH15 monomer with occupied glycosylation sites shown as sticks.
Comparison of RMSD (Å) for HA monomers.
| avH8 | avH11 | avH14 | avH15 | swH4 | |
|---|---|---|---|---|---|
| H1_1RD8 | 1.23 | 1.26 | 1.69 | 1.90 | 1.85 |
| H1pdm_3M6S | 1.22 | 1.18 | 1.63 | 1.75 | 1.69 |
| H2_2WRC | 1.29 | 1.23 | 1.56 | 1.55 | 1.63 |
| H3_4WE4 | 1.73 | 1.77 | 0.68 | 1.20 | 0.70 |
| H5_2FK0 | 1.47 | 1.24 | 1.40 | 1.53 | 1.39 |
| H6_4WST | 1.31 | 1.20 | 1.63 | 1.90 | 1.63 |
| H7_6D7C | 1.43 | 1.83 | 1.18 | 0.86 | 1.09 |
| H9_1JSD | 1.28 | 1.30 | 1.77 | 1.73 | 1.77 |
| H10_WSX | 1.79 | 1.79 | 1.25 | 0.93 | 1.30 |
| H13_4KPQ | 1.34 | 1.44 | 1.55 | 1.76 | 1.50 |
| H16_4F23 | 1.43 | 1.55 | 1.66 | 1.61 | 1.67 |
| H17_4I78 | 1.34 | 1.57 | 1.32 | 1.26 | 1.37 |
| H18_4K3X | 1.25 | 1.34 | 1.74 | 1.80 | 1.67 |
Figure 3Superimpositions of all available HAs. A. The rotation of head domain is represented by the 190-helix in the RBS of each HA subtype. The long α helix of the HA2 was used to perform superimposition of different subtype HAs. B. The overlap of interhelix. The PDBs used in the alignment are: H1_1RD8, H1pdm_3M6S, H2_2WRC, H3_4WE4, H5_2FK0, H6_4WST, H7_6D7C, H9_1JSD, H10_4WSX, avH11, H13-4KPQ, avH14, avH15, H16_4F23, H17_4I78, H18_4K3X.
The head rotation among different subtype HAs.
| Group-1 (comparing to H1pdm) | Group-2 (comparing to H3) | ||
|---|---|---|---|
| H1 | 9.54° | H4 | 6.07° |
| H2 | 7.07° | H7 | 3.10° |
| H5 | 4.54° | H10 | 0.93° |
| H6 | 5.54° | H14 | 3.49° |
| H8 | 11.11° | H15 | 4.65° |
| H9 | 13.01° | ||
| H11 | 8.64° | ||
| H13 | 5.97° | ||
| H16 | 13.19° | ||
| H17 | 14.83° | ||
| H18 | 7.82° | ||
H1pdm vs H3 is 27.67°.
Figure 4Superimposition of swH4, avH8, avH11, avH14 and avH15 RBS. The alignment was performed using the 190-helix. The three structural components and highly conserved RBS residues are labeled. The HA colors are consistent with those used in Figure 3.
Figure 5Glycan microarray analyses of avHAs. A. avH8. B. avH11. C. H14. D. avH15. Colored bars distinguish glycans that contain avian-type α2-3 sialic acid (blue) and human-type α2-6 sialic acid (red). Error bars arestandard deviations from six independent replicates on the array. Each of the numbered glycans' structures are listed in Table 6.
Glycans present on version 1 microarrays.
| Glycan No. | Structure |
|---|---|
| 1 | Neu5Acα |
| 2 | Neu5Acα |
| 3 | Neu5Acβ |
| 4 | Neu5Acα2-3(6-O-Su)Galβ1-4GlcNAcβ |
| 5 | Neu5Acα2-3Galβ1-3[6OSO3]GalNAcα |
| 6 | Neu5Acα2-3Galβ1-4[6OSO3]GlcNAcβ |
| 7 | Neu5Acα2-3Galβ1-4(Fucα1-3)[6OSO3]GlcNAcβ |
| 8 | Neu5Acα2-3Galβ1-3[6OSO3]GlcNAcβ |
| 9 | Neu5Acα2-3Galβ1-3(Neu5Acα2-3Galβ1-4)GlcNAcβ |
| 10 | Neu5Acα2-3Galβ1-3(Neu5Acα2-3Galβ1-4GlcNAcβ1-6)GalNAcα |
| 11 | Neu5Acα2-3Galβ1-4GlcNAcβ1-2Manα1-3(Neu5Acα2-3Galβ1-4GlcNAcβ1-2Manα1-6)Manβ1-4GlcNAcβ1-4GlcNAcβ |
| 12 | Neu5Acα(2-3)-Galβ(1-4)-GlcNAcβ(1-3)-Galβ(1-4)-GlcNAcβ(1-2)-Manα(1-3)-[Neu5Acα(2-3)-Galβ(1-4)-GlcNAcβ(1-3)-Galβ(1-4)-GlcNAcβ(1-2)-Manα(1-6)]-Manβ(1-4)-GlcNAcβ(1-4)-GlcNAcβ |
| 13 | Neu5Acα2-3Galβ |
| 14 | Neu5Acα2-3Galβ1-3GalNAcα |
| 15 | Neu5Acα2-3Galβ1-3GlcNAcβ |
| 16 | Neu5Acα2-3Galβ1-3GlcNAcβ |
| 17 | Neu5Acα2-3Galβ1-4Glcβ |
| 18 | Neu5Acα2-3Galβ1-4Glcβ |
| 19 | Neu5Acα2-3Galβ1-4GlcNAcβ |
| 20 | Neu5Acα2-3Galβ1-4GlcNAcβ |
| 21 | Neu5Acα2-3GalNAcβ1-4GlcNAcβ |
| 22 | Neu5Acα2-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ |
| 23 | Neu5Aca2-3Galβ1-3GlcNAcβ1-3Galβ1-4GlcNAcβ |
| 24 | Neu5Acα2-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ |
| 25 | Neu5Acα2-3Galβ1-4GlcNAcβ1-3Galβ1-3GlcNAcβ |
| 26 | Neu5Acα2-3Galβ1-3GalNAcα |
| 27 | Galβ1-3(Neu5Acα2-3Galβ1-4(Fucα1-3)GlcNAcβ1-6)GalNAcα |
| 28 | Neu5Acα2-3Galβ1-3(Fucα1-4)GlcNAcβ |
| 29 | Neu5Acα2-3Galβ1-4(Fucα1-3)GlcNAcβ |
| 30 | Neu5Acα2-3Galβ1-4(Fucα1-3)GlcNAcβ |
| 31 | Neu5Acα2-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ |
| 32 | Neu5Acα2-3Galβ1-3[Fucα1-4]GlcNAcβ1-3Galβ1-4[Fucα1-3]GlcNAcβ |
| 33 | Neu5Acα2-3Galβ1-3[Fucα1-3]GlcNAcβ1-3Galβ1-4[Fucα1-3]GlcNAcβ |
| 34 | Neu5Acα2-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ |
| 35 | Neu5Acα2-3(GalNAcβ1-4)Galβ1-4GlcNAcβ |
| 36 | Neu5Acα2-3(GalNAcβ1-4)Galβ1-4GlcNAcβ |
| 37 | Neu5Acα2-3(GalNAcβ1-4)Galβ1-4Glcβ |
| 38 | Galβ1-3GalNAcβ1-4(Neu5Acα2-3)Galβ1-4Glcβ |
| 39 | Fucα1-2Galβ1-3GalNAcβ1-4(Neu5Acα2-3)Galβ1-4Glcβ |
| 40 | Fucα1-2Galβ1-3GalNAcβ1-4(Neu5Acα2-3)Galβ1-4Glcβ |
| 41 | Neu5Acα2-6Galβ1-4[6OSO3]GlcNAcβ |
| 42 | Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-3(Galβ1-4GlcNAcβ1-2Manα1-6)Manβ1-4GlcNAcβ1-4GlcNAcβ |
| 43 | Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-3(Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-6)Manβ1-4GlcNAcβ1-4GlcNAcβ |
| 44 | Neu5Acα2-6Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-2Manα1-3[Neu5Acα2-6Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-2Manα1-6]Manβ1-4GlcNAcβ1-4GlcNAcβ |
| 45 | Neu5Acα2-6Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-2Manα1-3[Neu5Acα2-6Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-2Manα1-6]-Manβ1-4GlcNAcβ1-4GlcNAcβ |
| 46 | Neu5Acα2-6Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3[Neu5Acα2-6Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-6]GalNAca |
| 47 | Neu5Acα2-6Galβ1-4GlcNAcβ1-3[Neu5Acα2-6Galβ1-4GlcNAcβ1-6]GalNAca |
| 48 | Neu5Acα2-6GalNAcα |
| 49 | Neu5Acα2-6Galβ |
| 50 | Neu5Acα2-6Galβ1-4Glcβ |
| 51 | Neu5Acα2-6Galβ1-4Glcβ |
| 52 | Neu5Acα2-6Galβ1-4GlcNAcβ |
| 53 | Neu5Acα2-6Galβ1-4GlcNAcβ |
| 54 | Neu5Acα2-6GalNAcβ1-4GlcNAcβ |
| 55 | Neu5Acα2-6Galβ1-4GlcNAcβ1-3GalNAcα |
| 56 | Neu5Acα2-6Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ |
| 57 | Neu5Acα2-6Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3GalNAcα |
| 58 | Neu5Aca2-6Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ |
| 59 | Neu5Acα2-6Galβ1-4GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ |
| 60 | Galβ1-3(Neu5Acα2-6)GlcNAcβ1-4Galβ1-4Glcβ-Sp10 |
| 61 | Neu5Acα2-6[Galβ1-3]GalNAca |
| 62 | Neu5Acα2-6Galβ1-4GlcNAcβ1-6[Galβ1-3]GalNAca |
| 63 | Neu5Acα2-6Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-6[Galβ1-3]GalNAca |
Figure 6A. The overall structure of swH4 monomer, with occupied glycosylation sites shown as sticks. B. The glycan microarray analysis of swHA. Colored bars distinguish glycans that contain avian-type α2-3 SA (blue), and human-type α2-6 SA (red).
Figure 7Glycan microarray analysis of swH4 HA compared to human and avian recHAs. A second glycan array containing only a limited set of glycans containing a mix of linear and biantennary α2-3 and α2-6 linked sialosides of different lengths (from 1 to 4 LacNAc repeats) and spotted onto the array at different glycan concentrations, were used to assess both HA binding specificity and avidity.
Numbers of virus isolates with different key residue combinations in the RBS of all H4 HA.
| H4 Receptor binding site residues | Number of virus isolates 2228 in total | |||
|---|---|---|---|---|
| 187(190) | 222(225) | 223(226) | 225(228) | |
| E | S | Q | G | 8 |
| E | D | Q | G | 1 |
| E | E | Q | G | 1 |
| E | G | Q | G | 2207 Consensus |
| E | G | L | S | 3 |
| E | G | Q | S | 3 |
| E | G | Q | A | 5 |
H3 numbering in parenthesis.
EPI8131: A/Swine/Ontario/01911-1/99 EPI8127: A/Swine/Ontario/01911-2/99 EPI718518: A/swine/Missouri/A01727926/2015.
EPI1177844: A/duck/Shiga/37/2007 EPI69006: A/environment/Maryland/1101/2006 EPI453348: A/northern pintail/Interior Alaska/10BM07242R0/2010.
Glycans present on version 2 microarrays.
| Glycan No. | Structure |
|---|---|
| 3′-LN | Neu5Acα2-3Galβ1-4GlcNAcβ |
| 3′-LNLN | Neu5Acα2-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ |
| 3′-LNLNLN | Neu5Acα2-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ |
| Bi-3′-LN | Neu5Acα2-3Galβ1-4GlcNAcβ1-2Manα1-3[Neu5Acα2-3Galβ1-4GlcNAcβ1-2Manα1-6]-Manβ1-4GlcNAcβ1-4GlcNAcβ |
| Bi-3′-LNLN | Neu5Acα2-3-Galβ1-4-GlcNAcβ1-3Galβ1-4GlcNAcβ1-2Manα1-3[Neu5Acα2-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-2Manα1-6]-Manβ1-4GlcNAcβ1-4GlcNAcβ |
| Bi-3′-LNLNLN | Neu5Acα2-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-2Manα1-3[Neu5Acα2-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-2Manα1-6]-Manβ1-4GlcNAcβ1-4GlcNAcβ |
| Bi-3′-LNLNLNLN | Neu5Acα2-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-2Manα1-3[Neu5Acα2-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4)GlcNAcβ1-2Manα1-6]-Manβ1-4GlcNAcβ1-4GlcNAcβ |
| 6′-LN | Neu5Acα2-6Galβ1-4GlcNAcβ |
| 6′-LNLN | Neu5Aca2-6Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ |
| 6′-LNLNLN | Neu5Aca2-6Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ |
| Bi-6′-LN | Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-3[Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-6]-Manβ1-4GlcNAcβ1-4GlcNAcβ |
| Bi-6′-LNLN | Neu5Acα2-6Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-2Manα1-3[Neu5Acα2-6Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-2Manα1-6]Manβ1-4GlcNAcβ1-4GlcNAcβ |
| Bi-6′-LNLNLN | Neu5Acα2-6Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-2Manα1-3[Neu5Acα2-6Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-2Manα1-6]-Manβ1-4GlcNAcβ1-4GlcNAcβ |
| Bi-6′-LNLNLNLN | Neu5Acα2-6 Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-2Manα1-3[Neu5Acα2-6Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-2Manα1-6]-Manβ1-4GlcNAcβ1-4GlcNAcβ |